Acute Cerebral Infarction
Conditions
Interventions
Experimental group:Beraprost sodium
Control group:Beraprost sodium placebo
Sponsors
Department of Neurology, Yongchuan Hospital of Chongqing Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age greater than 18 years, gender not restricted; 2. Meets the diagnostic criteria for acute ischemic stroke; 3. Enrollment time within 24 hours of onset; 4. Good compliance, agrees to sign informed consent, and accepts follow-up.
Exclusion criteria
Exclusion criteria: 1. Patients who are intolerant to atorvastatin and rosuvastatin; 2. History of major surgery or endovascular treatment within 3 months before the screening period; 3. Arterial stenosis or occlusion not caused by atherosclerosis, such as arterial dissection, moya-moya disease, vasculitis, radiation-induced vascular disease, or fibromuscular dysplasia; 4. Abnormal liver function (ALT > 3 times the upper limit of normal); 5. Renal insufficiency (eGFR < 45 mL/min/1.73m^2); 6. Thrombocytopenia (PLT < 100 G/L); 7. Expected lifespan < 6 months; 8. During the screening period, having other known life-threatening diseases (such as hematologic diseases, malignant tumors), unstable vital signs, or requiring continuous monitoring or in a state of near death; 9. Patients enrolled in other studies that conflict with this study; 10. Known allergy to any product or component during the administration period; 11. Pregnant women, those breastfeeding, planning to become pregnant, or any other conditions deemed unsuitable for enrollment by the investigator; 12. Any other conditions deemed unsuitable for inclusion by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Neurological function score; | — |
Countries
China
Contacts
Public ContactYang Zhao
Yongchuan Hospital of Chongqing Medical University
Outcome results
None listed